Detailed Abstract
[Liver Oral Presentation 3]
[LV OP 3-3] Enhanced liver regeneration of the secretome released from ASCs by PGC-1α-driven upregulation of mitochondrial proliferation
Say-June KIM*2, Jung Hyun PARK1, Kee-Hwan KIM5, Ho Joong CHOI2, Dong Do YOU3, Kwang Yeol PAIK4, Jae Hyun HAN3, Tae Ho HONG2
1Department of Surgery, Eunpeong St. Mary's Hospital, College of Medicine, the Catholic University of Korea, Korea
2Department of Surgery, Seoul St. Mary’s Hospital, College of Medicine, the Catholic University of Korea, Korea
3Department of Surgery, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Korea
4Department of Surgery, Yeouido ST. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Korea
5Department of Surgery, Uijeongbu St. Mary's Hospital, College of Medicine, the Catholic University of Korea, Korea
Introduction : Peroxisome proliferator activated receptor λ coactivator 1α (PGC-1α) is a potent regulator of mitochondrial biogenesis and energy metabolism. In this study, we investigated the therapeutic potential of the secretome released from the adipose-derived stem cells (ASCs) transfected with PGC-1α (PGC-secretome).
Methods : We first generated PGC-1α-overexpressing ASCs by transfecting ASCs with the plasmids harboring the gene encoding PGC-1α. Secretory materials released from PGC-1α-overexpressing ASCs were collected and their therapeutic potential was determined using in vitro (thioacetamide [TAA]-treated AML12 cells) and in vivo (70% partial hepatectomized mice) models of liver injury.
Results : In the TAA-treated AML12 cells, the PGC-secretome significantly increased cell viability, promoted expression of proliferation-related markers, such as PCNA and p-STAT, and significantly reduced the levels of ROS. In the mice, PGC-secretome injections significantly increased both liver tissue expression of proliferation-related markers than did normal secretome injections (P < 0.05). We demonstrated that the PGC-secretome does not only have higher antioxidant and anti-inflammatory properties, but also has a potential of significantly enhancing liver regeneration in both in vivo and in vitro models of liver injury.
Conclusions : Reinforcing the mitochondrial antioxidant potential by transfecting ASCs with PGC-1α could be one of the effective strategies to enhance the therapeutic potential of ASCs.
Methods : We first generated PGC-1α-overexpressing ASCs by transfecting ASCs with the plasmids harboring the gene encoding PGC-1α. Secretory materials released from PGC-1α-overexpressing ASCs were collected and their therapeutic potential was determined using in vitro (thioacetamide [TAA]-treated AML12 cells) and in vivo (70% partial hepatectomized mice) models of liver injury.
Results : In the TAA-treated AML12 cells, the PGC-secretome significantly increased cell viability, promoted expression of proliferation-related markers, such as PCNA and p-STAT, and significantly reduced the levels of ROS. In the mice, PGC-secretome injections significantly increased both liver tissue expression of proliferation-related markers than did normal secretome injections (P < 0.05). We demonstrated that the PGC-secretome does not only have higher antioxidant and anti-inflammatory properties, but also has a potential of significantly enhancing liver regeneration in both in vivo and in vitro models of liver injury.
Conclusions : Reinforcing the mitochondrial antioxidant potential by transfecting ASCs with PGC-1α could be one of the effective strategies to enhance the therapeutic potential of ASCs.
SESSION
Liver Oral Presentation 3
Room A 7/28/2020 8:24 AM - 8:31 AM